首页|Recombinase polymerase amplification integrated with microfluidics for nucleic acid testing at point of care
Recombinase polymerase amplification integrated with microfluidics for nucleic acid testing at point of care
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NSTL
Elsevier
Nucleic acid testing (NAT) implemented on a portable, miniaturized, and integrated device with rapid and sensitive results readout is highly demanded for pathogen detection or genetic screening at resource-limited settings, especially after the outbreak of coronavirus disease 2019 (COVID-19). The integration of recombinase polymerase amplification (RPA) with emerging microfluidics, classified by paper-based microfluidics and chip-based microfluidics, shows great potential to perform laboratory independent NAT assays at point of care with minimal labor, time and energy consumption. This review summarizes the state-of-the-art of RPA integrated with paper-based microfluidics and chip-based microfluidics, and discusses their pros and cons. Finally, existing challenges and possible ways for optimization of microfluidics-based RPA are proposed.
Paper microfluidicsPathogen detectionIsothermal amplificationDigital RPAISOTHERMAL AMPLIFICATIONCHEMICAL INITIATIONASSAYMULTIPLEXPAPERDNAQUANTIFICATIONVIRUSTIME
NSTL
Elsevier
